Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

  1. Antolín Novoa, S.
  2. Escrivá-de-Romaní, S.
  3. Tolosa Ortega, P.
  4. Oliva Fernández, L.
  5. López López, R.
  6. López González, A.
  7. de la Morena Barrio, P.
  8. Echavarria Díaz-Guardamino, I.
  9. Alés Martinez, J.E.
  10. Garate, Z.
  11. González-Cortijo, L.
Journal:
Cancer Treatment and Research Communications

ISSN: 2468-2942

Year of publication: 2023

Volume: 37

Type: Article

DOI: 10.1016/J.CTARC.2023.100772 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus